May 29, 2024Open Access

Supplemental Figure 2 from Efficacy and Safety of Atezolizumab and Bevacizumab in Appendiceal Adenocarcinoma

Key Points

Key points are not available for this paper at this time.

Abstract

Supplementary Figure 2: Representative Pathology Images A,B: Representative images from patient tumor biopsies large mucin deposits and minimal cellularity. Infiltrating lymphocytes are notable in both images.

Read Full Paperexternally

Demander à l'IA

Bookmark

View Full Paper

Cite This Study

Hornstein et al. (Wed,) studied this question.

synapsesocial.com/papers/68e67f58b6db643587608588 https://doi.org/https://doi.org/10.1158/2767-9764.25922598

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplemental Figure 2 from Efficacy and Safety of Atezolizumab and Bevacizumab in Appendiceal Adenocarcinoma2024
2TABLE 1 from Efficacy and Safety of Atezolizumab and Bevacizumab in Appendiceal Adenocarcinoma2024
3TABLE 1 from Efficacy and Safety of Atezolizumab and Bevacizumab in Appendiceal Adenocarcinoma2024
4Data from Efficacy and Safety of Atezolizumab and Bevacizumab in Appendiceal Adenocarcinoma2024
5Supplementary Data from Circulating and intratumoral immune determinants of response to atezolizumab plus bevacizumab in patients with variant histology or sarcomatoid renal cell carcinoma2024

Demander à l'IA

Bookmark

View Full Paper